GUIDELINES ON THE INSERTION AND MANAGEMENT OF CENTRAL VENOUS ACCESS DEVICES IN ADULTS

British Committee for Standards in Haematology

Writing Group:

Liz Bishop¹; Lisa Dougherty²; Andrew Bodenham³; Janine Mansi¹; Paul Crowe⁴; Chris Kibbler⁵; Muriel Shannon⁶; Jennifer.Treleaven²

Address for correspondence:

BSCH Secretary
British Society for Haematology
100 White Lion street
London
N1 9PF

e-mail  bcsh@b-s-h.org.uk

Disclaimer.
While the advice and information in these guidelines is believed to be true and accurate at the time of going to press, neither the authors, the British Society for Haematology nor the publishers accept any legal responsibility for the content of these guidelines.

¹ Guys & St Thomas Hospital, London
² Royal Marsden Hospital, Sutton, Surrey
³ Consultant Anaesthetist, Leeds Royal Infirmary, Leeds
⁴ Birmingham Heartlands Hospital, Birmingham
⁵ Royal Free Hospital, London
⁶ St George’s Hospital London
These guidelines are a review of basic principles and relevant research for medical and nursing staff involved in the care of patients with central venous access devices (CVADs). They complement existing guidelines for nursing staff (RCN 2005) and are based on database searches using appropriate keywords, and a review of the existing published guidelines written by expert groups (British Committee for Standards in Haematology [BCSH], 1997). The authors were selected to embrace a wide range of interest in central venous access devices, including clinical, haematological, radiological, anaesthetic, critical care and nursing. The guidelines are not intended as a substitute for local policies and protocols but should provide a useful source of reference for those writing such documents. These guidelines relate to the insertion and management of non-tunnelled and skin-tunnelled central venous catheters (CVC), apheresis catheters, implanted ports and Peripherally Inserted Central Catheters (PICCs).

**Major recommendations**

Following a review of the current literature, which is fully referenced in the body of the paper, the following recommendations are made.

1. Patients should receive clear and comprehensive verbal and written information explaining the risks, benefits and care of the catheter. Signed consent should be obtained prior to catheter insertion.
2. Non-tunnelled catheters are indicated for short-term use when peripheral venous access is impractical.
3. Tunneled central venous catheters are indicated for the repeated administration of chemotherapy, antibiotics, parenteral feeding and blood products, and for frequent blood sampling. They are recommended for patients in whom long-term (>30 days) central venous access is anticipated.
4. Fully implanted catheters (ports) are more suitable for children and for less frequent accessing but long-term use, whereas skin-tunnelled catheters are recommended for intensive access.
5. PICCs should be avoided for in-patient therapy because of limited catheter longevity and increased incidence of thrombosis. They are more suited to ambulatory or out-patient based therapy.
6. Polyurethane PICCs allow easier infusion of blood products as greater flow rates are achieved because the thinner walls provide a larger internal diameter of the catheter. The decision to use polyurethane catheters should be balanced against the higher risk of thrombosis with these catheters compared to silicone catheters.
7. The number of lumina and diameter of catheters should be kept to the minimum.
8. Experienced operators, regardless of speciality, should perform catheter insertion with training, supervision and competence assessment programs in place. Paediatric specialists should insert catheters in children.
9. Ultrasound guided insertion is recommended for all routes of central venous catheterisation. The use of ultrasound is also recommended for the insertion of PICCs when the peripheral veins are not visible or palpable.
10. Imaging facilities (fluoroscopy, intravenous contrast studies and standard radiography) should be available for the insertion of skin-tunnelled CVCs and ports.
11. Catheter insertion should take place in an operating theatre or similar clean environment. Bedside placement should not be performed except in an emergency, apart from PICC placement.
12. Rigorous skin cleansing with a chlorhexidine gluconate 2% in alcohol or aqueous solution is recommended prior to catheter insertion.
13. Antibiotic/antimicrobial impregnated catheters, for example chlorhexidine and silver sulfadiazine impregnated catheters should be considered for appropriate risk groups of patients in order to minimise infection risk. These are becoming available for tunnelled devices.
14. Routine antibiotic prophylaxis is not recommended.
15. Flushing with heparin versus normal saline remains controversial.
16. Routine replacement, for example, weekly change, of short-term catheters as a means to reduce infection rates is not recommended.
17. Guidewire-assisted catheter exchange to replace a malfunctioning catheter is acceptable if there is no evidence of infection. However, if infection is suspected the existing catheter should be removed and a new catheter inserted at a different site. This technique is generally impractical for cuffed tunnelled catheters or ports when it may be technically easier and safer to insert a new catheter into a clean site.
18. Dressings should be changed 24 hours after catheter insertion and weekly thereafter.
19. Securing devices, for example, Statlok™ are preferable to stitches, and lines should not be sewn into or around the vein.
20. Needle-free connectors should be used to reduce risk of infection to patients and needle stick injury to staff.
21. A positive pressure method of flushing (by protocol, according to the type of catheter) is essential to maintain catheter patency.
22. IV therapy giving sets should be changed every 24-48 hours if used for transfusing blood products, and every 72-96 hours otherwise.
23. Pre-existing haemorrhagic, thrombotic or infective problems must be effectively managed before catheter insertion.
24. Blood products may be administered concurrently with another drug/infusion through a dual bore catheter.
25. Low-dose warfarin prophylaxis is not recommended, but therapeutic dosing may be required in selected patients at risk of developing a thrombosis.
26. Thrombosis and infection must be promptly diagnosed and vigorously treated. Both complications may require removal of the catheter.
27. Tunnelled catheters can be pulled out if the cuff has not anchored in the tissues. Otherwise, a cut-down procedure is needed to free the cuff. Ports require surgical removal. All procedures should be undertaken by experienced personnel.
28. Units should audit complications associated with central venous catheterisation and use the data to develop preventative measures. Close liaison with the local microbiology department is essential to monitor trends in infection.

1. Indications for catheter insertion

These catheters are indicated (a) when venous access is poor, (b) when embarking on prolonged intravenous chemotherapy and/or Total Parenteral Nutrition (TPN), or for repeated administration of blood products, (c) when intravenous therapy involves drugs known to be venous sclerosants, (d) when ambulatory chemotherapy is to be given as an out-patient, (e) in the situation of repeated sampling or venesection.

2. Choice of catheter
Catheters are categorised into (a) non-tunneled catheters, (b) tunneled catheters with anchoring cuff, (c) implanted ports (d) apheresis/dialysis catheters (tunneled and non-tunneled) and (e) PICCs. They may have single or multiple lumina and can be open ended or valved. Multiple lumina catheters are advantageous in patients undergoing stem cell transplantation or chemotherapy where a number of agents and blood products require simultaneous infusion. Blood products may be administered concurrently with another drug/infusion through a dual bore catheter. Multiple lumina catheters are associated with increased morbidity (Dezfulian et al 2003; Farkas et al 1992), but in the haematology setting, the increased risk is likely to be offset by the convenience of multi-lumina catheters, thereby justifying their use. If TPN is being administered, a single lumen central venous catheter or lumen should be dedicated exclusively to this purpose (Pratt et al 2001). The smallest diameter catheter should be employed, to minimise the risk of catheter-related thrombosis and/or subsequent venous stenosis (Knutstad et al 2003). However, it may be difficult to administer blood products via very narrow lumina.

(a) Non-tunneled central venous catheters

In an attempt to reduce catheter-related blood stream infection (CRBSI) rates, various materials have been investigated. These have been reviewed, and antimicrobial/antiseptic impregnated catheters, for example, chlorhexidine and silver sulfadiazine short-term catheters have been shown to be effective in reducing catheter-related blood stream infections, but other types are commercially available. A large randomised controlled trial showed that CVCs coated with chlorhexidine and silver sulfadiazine were associated with a 44 % reduction in colonisation and a 79 % reduction in catheter-related blood stream infection (Maki et al 1997), although the largest study to date, in which the mean duration of catheterisation was 20+/-12 days, failed to show any benefit (Logghe et al 1997). The use of antimicrobial/antiseptic impregnated catheters is recommended for adults who require short-term (<10days) central venous catheterisation and who are at high risk of infection (Pratt et al 2001; Pellowe et al 2003). The debate continues about such catheters and their propensity for inducing antibiotic resistance, and occasional severe allergic reactions have been reported (Cicalini et al 2004).

(b) Tunneled catheters

Tunneled catheters are recommended for patients in whom long-term (>30 days) central venous access is necessary (Pratt et al 2001). Devices exist with and without Dacron anchoring cuffs. Tunneled catheters have been shown to be associated with lower infection rates than non-tunneled catheters (Randolph et al 1998). The cuff induces an inflammatory reaction within the subcutaneous tunnel leading to fibrosis, with catheter fixation usually occurring within 3-4 weeks of insertion. Valved catheters have the advantage of not requiring heparin flushes but may need pressurised infusions to administer blood products. They also tend to be more costly. There is little hard evidence to support one type of catheter over another.

(c) Implanted ports

Ports have been shown to have the lowest reported rates of catheter-related blood stream infections compared to either tunneled or non-tunneled CVC (Groeger et al 1993; Pegues et al 1992). Most ports are single lumen, which makes them more suited to long-term intermittent therapy. They tend to be used more frequently in paediatrics,
and in patients with solid tumours (Camp-Sorrell 1992; Gabriel 1999). In the adult haematology setting, they may be of use in sickle cell anaemia or thalassaemia, where patients are receiving regular blood transfusions. Ports may also be useful for oncology patients with poor peripheral venous access who are receiving less intensive therapy unlikely to cause prolonged neutropenia. They allow less restricted bathing and swimming and may appeal to patients concerned about the psychological aspects of the presence of the external part of the non-implanted catheters. They are more expensive to purchase, insert and remove, and they leave larger scars.

(d) Apheresis/dialysis catheters

These can be either non-tunneled (Vascaths™) or subcutaneously tunnelled with a cuff, and a selection is commercially available for longer-term use. They are larger bore catheters and usually require flushing with stronger solutions of heparin to maintain patency (eg 5,000 units per ml of heparin). The volume of heparin flush used should be equal to the volume of each lumen to avoid systemic heparinisation of the patient.

It should be noted that for optimum flow rates, it may be necessary to position the tip of the catheter at the junction of the right atrium and superior vena cava (SVC) (Veseley 2003) in order to avoid irritation / thrombus formation when the catheter tip abuts onto the vein wall (Fletcher & Bodenham 2000).

(e) PICCs

PICCs represent a vascular access device (VAD) that can be considered to have an intermediate role in central venous access. These catheters are usually inserted at the bedside via an antecubital vein and are available with single or multiple lumina. In the haematology setting they are well suited for ambulatory or out-patient therapy (Whitman 1996) as opposed to intensive in-patient therapy but have been shown to be associated with a higher incidence of thrombosis in patients with haematological malignancies (Cortelezzi et al 2005; 2005). This is an important consideration in patients who have had previous thromboses, and in those who are receiving therapy which may increase the thrombotic tendency, such as thalidomide. PICCs can be made of either silicon rubber or polyurethane, the former being associated with a lower risk of thrombosis (Galloway and Bodenham 2004). However, polyurethane PICCs are recommended because polyurethane is a tougher material, enabling thinner lumen walls and larger internal diameters of the lumina. This significantly increases flow rates and reduces the potential for breakage and rupture of the catheter (Hadaway 1995; Mayer & Wong 2002). This is an advantage due to the volume of blood and platelet infusions required by haematology patients.

The various types of catheter available are summarized in Table 1. An experienced member of the haemato-oncology team should make the decision regarding which type of catheter is most appropriate at the outset of therapy, to avoid multiple catheterisations. The decision should be made based on diagnosis, length and type of therapy, patient preference, clinical status, availability of patent veins, operator experience and previous central venous access history (Chernecky et al 2002; Hamilton 2000; Hamilton & Fermo 1998). For example, if an allogeneic transplant is planned, a double or triple lumen skin-tunneled catheter should be inserted at the outset to ensure adequate access throughout chemotherapy and the subsequent transplant.
<table>
<thead>
<tr>
<th>Catheter type</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tunnelled catheters</td>
<td>Choice of sites</td>
<td>Short-term use</td>
</tr>
<tr>
<td></td>
<td>Easy to insert and remove</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multiple lumina available</td>
<td></td>
</tr>
<tr>
<td>*Skin-tunnelled catheters</td>
<td>Lower infection rates than non-tunnelled</td>
<td>More complex insertion and removal</td>
</tr>
<tr>
<td></td>
<td>Long-term use</td>
<td></td>
</tr>
<tr>
<td>Ports</td>
<td>No external catheter</td>
<td>Surgical insertion and removal</td>
</tr>
<tr>
<td></td>
<td>Cosmetically attractive</td>
<td>Less suitable for frequent repeated access</td>
</tr>
<tr>
<td></td>
<td>Patient can swim/bathe as normal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low maintenance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Long-term use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lower infection rates than skin-tunnelled catheters</td>
<td></td>
</tr>
<tr>
<td>Apheresis/dialysis catheters</td>
<td>Permit high blood flow rates</td>
<td>Large bore</td>
</tr>
<tr>
<td></td>
<td>Easier to insert and remove</td>
<td>Require flushing with concentrated heparin (for example 5,000u/ml, according to manufacturer guidelines)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>solution to maintain patency. Flush solution must be withdrawn prior to use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Short-term use</td>
</tr>
<tr>
<td>Non-tunnelled (e.g. Vascath™ Kimal)</td>
<td></td>
<td>Complex insertion and removal</td>
</tr>
<tr>
<td></td>
<td>Lower infection rates than non-tunnelled devices</td>
<td>Best inserted via internal jugular or femoral routes</td>
</tr>
<tr>
<td>Skin-tunnelled</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Good for patients with poor peripheral access who require both PBSC harvest and transplant procedure</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PICCs</td>
<td>Easy to insert and remove</td>
<td>Higher thrombosis rate particularly with polyurethane variety</td>
</tr>
<tr>
<td></td>
<td>Do not require platelet support or correction of clotting prior to insertion/removal</td>
<td>Polyurethane variety required to infuse blood/platelets because have greater internal diameter than</td>
</tr>
<tr>
<td></td>
<td></td>
<td>silicone variety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Slower flow rates particularly in silicone/valved varieties</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Catheter longevity lower than with skin-tunnelled devices</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Incidence of malposition greater than in other types of CVC</td>
</tr>
</tbody>
</table>
Valved skin-tunnelled catheters are not suitable for apheresis, whereas occasionally the other types of skin-tunnelled catheters can be used for returning blood during an apheresis procedure.

3. Patient care prior to catheter insertion

The procedure, including risks and benefits, should be explained to the patient. The “operator” should undertake a physical assessment, vein assessment and history of previous central venous catheterisations. Small, portable ultrasound imaging devices provide quick confirmation of vein patency. The presence of venous collaterals on the chest wall/abdomen may signify deep venous obstruction. A history, or signs of SVC obstruction is highly significant, as is a history of difficulties or failure of insertion by a competent operator using X-ray screening or ultrasound. If there is a history of a prior thrombus it is prudent to perform formal ultrasound imaging studies with Doppler measurements, on both the affected and unaffected side, to exclude thrombus and ensure vein patency. Ultrasound gives useful information at most sites but cannot image the SVC. Other modalities including conventional venography, CT with contrast, MRI venography and transoesophageal ultrasound all have advantages. Difficult, or potentially difficult cases should be discussed with a vascular radiologist. Stenting techniques can be used to restore patency to stenosed veins.

It is generally accepted that the platelet count should be greater than 50 x 10^9/litre prior to insertion of a catheter other than a PICC (BCSH 2003), and the INR less than 1.5. (Douketis et al, 2004; Ansell et al 2004) Problems may arise when patients are refractory to platelets, have idiopathic thrombocytopenic purpura (ITP) or thrombotic thrombocytopenic purpura (TTP), or in the presence of deranged clotting, for example, in acute promyelocytic leukaemia. The risks and benefits of insertion in terms of type and site of catheter must be assessed on an individual basis. Where the risk of bleeding is increased, or when difficulties with insertion are anticipated, use of experienced personnel and ultrasound guidance are essential (Hatfield & Bodenham 1999) in order to maximise the likelihood of an atraumatic, “first pass” procedure. Additionally, use of lidocaine with adrenaline 1:200,000 as local anaesthetic will reduce subcutaneous bruising / bleeding. The increasing recognition of the risks associated with the use of blood products mandates assessment of need on an individual basis rather than routine correction of all minor abnormalities of platelet count and coagulation studies.

4. Antibiotic prophylaxis

In a meta-analysis of published research, the Center for Disease Control in the United States of America (O’Grady et al, 2002) identified that the use of antimicrobial prophylaxis routinely before insertion or during use of an intravascular catheter does not prevent catheter colonization or BSI (evidence level 1A; i.e. strongly supported by well-designed experimental, clinical, or epidemiologic studies).

The Department of Health (Pratt et al 2001) has issued guidelines limiting the use of vancomycin. They state that the agent should not be used in the following circumstances:

- as treatment in response to a single blood culture positive for coagulase-negative staphylococcus, if other blood cultures drawn in the same time frame are negative
• for routine prophylaxis,
• when there is a catheter-related infection involving beta-lactam-sensitive organisms
• as continued empiric therapy for presumed infections in patients whose cultures are negative for beta-lactam-resistant gram-positive organisms.

Antibiotic cover may be appropriate if simultaneous insertion and removal procedures have to be performed in a known case of catheter-related sepsis. However, it is not routinely recommended.

5. Catheter insertion

As previously mentioned, it is essential that only experienced personnel insert central venous catheters, to minimize infection and other complications, particularly in the presence of low platelets, deranged clotting and/or in the critically ill patient. This includes the short-term multiple lumina non-tunnelled catheter, which is often inserted by junior medical personnel who have undergone minimal training with little clinical supervision in insertion techniques.

Where possible, the procedure should be performed in a clean area designated for CVC insertion such as the X-ray department, operating theatre, or a procedure suite where a high standard of asepsis is practiced. Units which currently insert tunnelled CVCs on the wards should audit their procedural complications and infection rates in order to support or refute continuation of this practice. Whatever the environment, maximum sterile barrier conditions (mask, cap, sterile gloves, gown and large drape) have been shown to lower the risk of acquiring catheter-related infections (Mermel et al 1991; O’Grady et al 2002; Raad et al 1994). Published evidence shows, however, that the risk of infection depends mainly on the presence of bacteria on the skin (Fletcher 2005). Hence, skin cleansing is the most important part of care before catheter insertion. Two per cent aqueous chlorhexidine has been shown to be superior to either povidone-iodine solution or 70% alcohol in reducing catheter-related blood stream infections (Maki et al, 1991). More recently, 2% chlorhexidine in alcohol has been recommended (Pratt et al 2001; Pellowe et al 2004) and this should be used for skin antisepsis prior to catheter insertion and for insertion site dressing changes.

Anatomical surface markings can be unreliable for the initial puncture and ultrasound guided insertion of catheters (excluding PICCs) is strongly recommended, whenever possible, by operators experienced in the use of ultrasound techniques (Hind et al 2003; NICE 2002). Ultrasound can be used for PICC insertion but is not usually necessary. It may, however, be useful to check vein patency, for proximal approaches or when the peripheral veins are not palpable because they lie deep within the subcutaneous tissue. The use of ultrasound ensures patency of the vein and has been shown to reduce insertion-related complications (NICE 2002; Hind et al 2003). An image intensifier can be used to image the target vein with contrast and to check correct positioning of the guidewire and catheter tip. Its use is recommended when inserting tunnelled catheters and ports. Catheters are normally inserted under local anaesthesia with, or without sedation such as intravenous midazolam or other combinations of sedative drugs, according to local policy. Occasional patients with severe needle phobia or who become dyspnoeic when lying flat/head down will require a general anaesthetic. The majority of procedures should be performed by Seldinger wire techniques, reserving open surgery
for difficult cases or small children. Specialist vascular radiology input will be required for the more difficult cases needing vein stenting or unusual routes of access.

No randomised controlled trials have satisfactorily compared infection or thrombosis rates for catheters placed via the jugular, subclavian and femoral sites (Pellowe et al 2004), although in non-randomised comparisons, infection rates are higher with femoral catheters (Goetz et al, 1998) [See below]. In adults, the subclavain approach may have an advantage because there is some evidence to suggest it has lower infection rates than the internal jugular approach (Mermel et al 1991; Richet et al 1990), but this must be balanced against the risks of mechanical complications. For example, catheters placed via a subclavian approach are more likely to cause thrombosis than those placed via the internal jugular route (Treretola et al 2000), and are therefore more likely to cause secondary stenosis (Knutstad et al 2003).

A lateral approach when using the subclavian vein avoids 'pinch off' of the catheter, which is a rare complication referring to entrapment of the catheter between the clavicle and the first rib (Polderman et al 2002). Ultrasound-guided insertions in the subclavian area will tend to move the puncture site laterally due to the presence of the probe and clavicle (Sharma et al 2004). An alternative is to use the internal jugular vein, which is particularly useful in patients with abnormal coagulation, as it reduces the risk of inadvertent arterial puncture (Lameris et al, 1990), although tunnelling can be more difficult. Debate continues based on retrospective audits concerning the relative merits of right or left insertion sites and the perceived differences in rates of thrombosis, infections and mechanical problems. Other considerations such as cosmetic appearance may be important to patients and care should be taken to avoid lumpy tunnelling in the neck and to arrange for the external portion of the line to be concealed under clothing.

In patients in whom the internal jugular and both subclavian veins are occluded or otherwise unavailable for puncture, or in the event of SVC obstruction, catheters may be inserted into the femoral vein, although infection rates are higher with this approach (Goetz et al 1998; O'Grady et al 2002), as are rates of deep vein thrombosis (Joynt et al 2000; Trottier et al 1995). Tunnelling can take the exit site out of the groin onto the relatively clean anterior abdominal wall. The femoral approach may also be useful in emergency situations or in the presence of severe thrombocytopenia and/or coagulopathy, where it is easier to apply pressure or achieve haemostasis in the event of bleeding. The straight course of the vein makes it ideal for stiff dialysis-type catheters which do not traverse tight angles easily.

With subcutaneous ports, subclavian or internal jugular venous access is achieved using aseptic conditions, in the same way as for skin-tunneled catheters. If patients are accessing their own port, then it should be located low on the rib cage or upper arm, for easy access. When patients are not accessing their own port, then the port is usually located on the upper rib cage near the clavicle. Ports near the sternum provide better needle stability and ease of access. Adequate subcutaneous tissue will prevent erosion through the skin. If the port is placed too deeply or there is excess adipose tissue, it can make access difficult. Placement under the arm, in the breast or the soft tissue of the abdomen should be avoided (Goodman 2000). There are both low and high profile ports available.
6. Immediate patient care after catheter insertion

Tip placement should be checked by X-ray prior to use and the position of the catheter tip documented in the patient file. Optimum tip position is the distal superior vena cava or the upper right atrium (Fletcher & Bodenham 2000). The carina can be used as an approximate marker of the level of the pericardial reflection. Catheters inserted from the left side tend to need the tip to lie at the junction of the SVC and RA or within the upper RA, in order for the catheter tip to lie within the long axis of the vessel. Changes in tip position on standing may be significant. Chest X-rays taken within 1-2 hours of placement may not demonstrate a slowly developing pneumothorax or bleed. A further chest X-ray is required if the patient becomes dyspnoeic or complains of laterat chest wall discomfort/pain. Pneumothorax usually relates to subclavian vein catheterisation but can also result from attempted internal jugular cannulation. Many pneumothoraces do not require drainage but should be monitored by serial X-rays. Smaller bore Seldinger-type drains are suitable for draining slowly accumulating collections when treatment is required, and large bore traditional chest drains are rarely required.

A transparent semi-occlusive dressing such as OpSite 1V 3000™ is recommended (Reynolds et al 1997; Treston-Aurend et al 1997). Transparent dressings reliably secure the device, permit continuous visual inspection of the catheter site, permit patients to bathe and shower without saturating the dressing, and require less frequent changes than do standard gauze and tape dressings. The dressing should be changed after the procedure if bleeding has occurred, but otherwise not until 24 hours post-operatively. It should then be changed weekly if there are no signs of bleeding and/or infection. However, a recent review has found no consistent benefit for any type of dressing (Gillies et al 2003). A meta-analysis has assessed studies that compared the risk for catheter-related BSIs for groups using transparent dressings versus groups using gauze dressing. The risk for CRBSIs did not differ between the groups. The choice of dressing can be a matter of preference. If blood is oozing from the catheter insertion site, gauze dressing might be preferred (O’Grady et al 2002).

For patients with a tunneled catheter, the upper suture over the insertion site into the vein should be removed at 7-10 days and the lower one at the exit point should be removed after 3 weeks. Recent evidence supports the use of securing devices, including tapes, adhesives or staples (Motonaga et al 2004), particularly with non-tunneled CVCs and PICCs. These obviate the need for sutures at the exit site or around the vein, which can cause difficulties with subsequent line removal. Securing devices have also been shown to reduce infection rates when compared with sutures (Crnich & Maki 2002; Frey & Schears 2006; Yamamoto et al 2002). Sutures over an implanted port insertion site are removed after 7-10 days, although some operators may use dissolvable sutures to close the wound. PICCs and non-tunneled catheters should always be covered with a dressing, although skin-tunnelled catheters may not require a dressing once the wound has healed (Morris et al 1995; O’Grady et al 2002). This can be reviewed on an individual basis. Implanted ports do not require any dressing once the wound has healed.

7. Long-term catheter care

For skin-tunneled devices it is advisable to either secure the ends to the chest wall with tape or to use a “neck-bag” to take the weight of the free ends. Showering is preferable
to bathing, and swimming must be avoided with any external catheter, in order to prevent colonization by Gram-negative organisms, especially *Pseudomonas* spp.

Flushing with the correct solution and technique is essential to maintain catheter patency, and only single-dose solutions should be used. The use of heparin flushes versus normal saline intermittent flushes remains controversial. Many clinicians still recommend the use of heparin (10u/ml) to prevent thrombus formation and ensure catheter patency, but the efficacy of this is unproven (Pellowe *et al* 2004). Exposure to heparin should be minimised to prevent the development of heparin-induced thrombocytopenia (HITS) and to avoid development of bleeding complications due to inadvertent heparinisation secondary to multiple heparin flushes (Passannante & Macik 1998). A review of the current evidence concluded that heparin doses of 10u/ml are no more beneficial than flushing with normal saline alone (Pellowe *et al* 2004). However, there are exceptions. For example, apheresis/dialysis catheters require heparin flushes to maintain patency, and some manufacturers and clinicians recommend heparin flushes, particularly when catheters are infrequently accessed. The need for heparin may be a function of bore, as larger bore catheters allow quicker back-tracking of blood up the lumen. Because thrombi and fibrin deposits on catheters might serve as a nidus for microbial colonization of intravascular catheters, the use of anticoagulants might have a role in the prevention of CRBSI. Because the majority of heparin solutions contain preservatives with antimicrobial activity, whether any decrease in the rate of CRBSI is a result of the reduced thrombus formation, the preservative, or both is unclear (O’Grady *et al* 2002).

Flushing protocols for the main types of catheter are shown in Table 2 although the manufacturers’ recommendations should always be followed. Syringe size can be important as the smaller syringes create greater pressure and may contribute to catheter rupture if excessive pressure is exerted (Conn 1993; Primhak *et al* 1998). Care must always be taken to maintain patency by using a pulsatile flush method and by maintaining positive pressure while removing the syringe at the end of flushing in order to avoid reflux of blood (Dougherty 2004; Goodwin & Carlson 1993). The use of needle-free connectors is recommended as these have been shown to reduce infection (Yebenes *et al* 2004).

Patients should be educated in the care of their catheters, and a recent randomised study has shown a reduction in catheter-related infections when patients are made responsible for care of the catheter (Moller *et al* 2005).

Several prospective and randomized studies have shown that specialist teams can reduce infection rates (Fitzimmons *et al* 1997; Hamilton 2004, Meier *et al* 1998, Miller *et al* 1996, Soifer *et al* 1998, Solomon & Stoddard 2001), and where possible the use of these should be developed. Infections can be minimised by careful hand washing and catheter site care. The external surfaces of the access port should be disinfected with a chlorhexidine gluconate solution unless contraindicated by the manufacturers instructions (Pellowe *et al* 2004; Pratt *et al* 2001). Either a sterile (sterile gloves) or ‘non-touch’ (clean gloves) technique must be utilised when accessing any CVC lumen. A blood sampling protocol should be developed locally, but must include instruction on the removal of the heparinised dead space (approximately 5 ml) prior to sampling, to avoid erroneous results. The volume to be removed before coagulation studies are performed is uncertain with central venous catheters, but for APTT studies from arterial cannulae it is recommended that 6 times the dead space volume is removed (Laxson & Titler,
Coagulation studies in such circumstances may produce erroneous results, particularly with apheresis or dialysis catheters where stronger heparin solutions have been used, and, if there is any doubt, the sample should be taken from a peripheral vein. In the bone marrow transplant setting, a lumen for taking blood for ciclosporin and other drug levels should be identified and the drugs administered through a different lumen.

Table 2: Catheter flushing protocols

<table>
<thead>
<tr>
<th>Catheter Type</th>
<th>Solution</th>
<th>Frequency</th>
<th>Cautions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-tunnelled</td>
<td>10ml saline 0.9% +/− 5ml heparinised saline solution (10u/ml)</td>
<td>After each access when used intermittently, or weekly</td>
<td></td>
</tr>
<tr>
<td>*Skin-tunnelled</td>
<td>10ml saline 0.9% +/− 5ml heparinised saline solution (10u/ml)</td>
<td>After each access or weekly</td>
<td></td>
</tr>
<tr>
<td>*Ports</td>
<td>10ml saline 0.9% +/− 5ml heparinised saline solution (10u/ml)</td>
<td>After each access or monthly</td>
<td>Do not use a syringe smaller than 10mls in size, to avoid catheter rupture</td>
</tr>
<tr>
<td>Apheresis/dialysis</td>
<td>10ml saline 0.9% plus 1000u/ml or 5000u/ml Catheter volume only</td>
<td>After each access or weekly</td>
<td>Calculate “dead space volume” to avoid systemic heparinisation – usually printed on the CVC lumen</td>
</tr>
<tr>
<td>*PICCs</td>
<td>10ml saline 0.9% +/− 5ml heparinised saline solution (10u/ml)</td>
<td>After each access, or at least weekly</td>
<td></td>
</tr>
</tbody>
</table>

*Valved varieties require 10ml saline 0.9% solution to flush. No heparin required. Refer to manufacturer guidelines in each case.

8. Patient information

A patient's guide should include the following sections: (a) What constitutes a central venous access device (b) The advantages and disadvantages of having a central venous access device (c) Any risks involved in the insertion of a central venous access device (d) Care of the device (e) Removal of the device
Locally generated patient information leaflets are recommended but should not be a substitute for careful and detailed explanation by a nurse/doctor experienced in the care of central venous catheters. Generally speaking, the following information must be provided, with a 24-hour cover arrangement:

- How to contact a nurse or doctor if the exit site is red, sore, oozing pus or in the event of a fever of > 38°C
- How to contact a nurse or doctor if the catheter becomes damaged or leaks
- How to contact a nurse or doctor if the arm becomes swollen or if any distended veins become apparent on the chest or neck
- How to contact a nurse or doctor if breathless or pain are experienced

9. Management of problem patients

(a) If the patient is thrombocytopenic and there is evidence of bleeding after catheter insertion, then the patient should receive further platelet transfusion(s) to maintain the count in excess of 50x10^9/L until bleeding stops, bearing in mind problems may exist in patients refractory to random donor platelets or in those suffering from ITP or TTP (BCSH Guidelines, 2003). In these situations the application of pressure dressings and topical tranexamic acid may help. Prolonged compression (15 minutes plus) will often stop bleeding. It should not be overlooked, however, that there are no published prospective, randomised studies to support or negate the theory that the level of platelet count at time of CVC insertion should be maintained above 50 x 10^9/L in order to reduce potential for significant bleeding problems. Barrera et al (1996) concluded that thrombocytopenia is not the only risk factor for bleeding and concludes that other variables such as insertion site, number of needle passes to cannulate the vein, and expertise are more pertinent. Similarly, the study by Ray & Shenoy (1997) concluded that peri-procedural platelet transfusions have little effect on bleeding outcome. Other studies in patients with liver disease and complex haemostatic defects have found that a platelet count of <50x10^9/L was an independent risk factor for bleeding in comparison to raised INR or prolonged PT (Doerfler et al 1996; Fisher & Mutimer 1999; Mumtaz et al 2000). Robust, randomised studies are necessary to achieve evidence-base guidance in these complex situations.

(b) In patients with disseminated intravascular coagulation, for example in association with acute promyelocytic leukaemia, there should be vigorous correction of any abnormality of coagulation. The prothrombin time should be <1.5 times normal and fibrinogen >1.0 g/1. Patients taking oral anticoagulants should stop their tablets to achieve an INR < 1.5 before catheter insertion. If time is limited, factor concentrates, fresh frozen plasma (FFP), or vitamin K may be required, but the latter, in high doses, may interfere with subsequent anticoagulation (BCSH Guidelines, 2005). Reversal of therapeutic anticoagulation with vitamin K is usually achieved within 4 to 6 hours of intravenous administration of vitamin K, and within 24 hours of oral administration (Watson et al 2001). Phytomenadione (Konakion®) doses of up to 2mg intravenously, or 5mg orally are recommended. Complete and rapid reversal of over anticoagulation is more readily achieved with a factor concentrate rather than with FFP (Evans et al 2001;
Makris et al 1997). Intravenous vitamin K should be given if reversal is to be sustained (Yasaka et al 2002), and repeat administration may be required after 24 hours.

Intravenous unfractionated heparin (UFH) should be stopped 3 hours before catheter insertion and restarted when haemostasis is secured. In patients receiving prophylactic subcutaneous low molecular weight heparin (LMWH), catheter insertion can be undertaken 12 hours after the last injection; for patients receiving therapeutic subcutaneous LMWH, the time to catheter insertion should be extended to 18 hours after the last injection. Heparin can be recommenced once the operator has confirmed haemostasis is secure, usually within 2 hours of catheter insertion. Substitution with intravenously infused UFH or insertion of an IVC filter should be considered if there is a very high thrombotic risk. Expert haematology advice should be sought.

(c) Haemophiliac patients (with haemophilia A, B or C) will require appropriate factor replacement, as may patients with other inherited coagulopathies Correction should be maintained for > 48 hours. Clinicians caring for such patients should seek advice from their local haemophilia reference centre.

(d) Infection at the time of catheter insertion represents a relative contra-indication to proceeding, and consideration should be given to temporary, non-tunnelled catheter placement or temporary use of peripheral cannulae, but the risks and benefits should be considered for each patient on an individual basis. If the patient has a unilateral skin infection on the anterior upper chest wall, the unaffected side should be used for catheter placement. Targeted antibiotic prophylaxis may be warranted in these cases.

Routine replacement of non-tunnelled CVCs should not be used as a method for preventing catheter-related infection, as this has not been shown to reduce infection rates (Cook et al 1997; O’Grady et al 2002). Guidewire-assisted catheter exchange to replace a malfunctioning catheter is acceptable if there is no evidence of infection. However, if infection is suspected, the existing catheter should be removed and a new catheter inserted at a different site (Pratt et al 2001). This technique is generally impractical for cuffed tunnelled catheters or ports, when it may be technically easier and safer to insert a new catheter into a clean site.

(e) A patient who has received previous radiotherapy to one side of the chest should have the catheter inserted on the opposite side. Patients who have undergone mastectomy and lymph node dissection should have the catheter placed on the opposite side. Catheters can be tunnelled onto the arm or other sites if the chest wall is unsuitable. Catheters should be kept away from breast prostheses and pacemaker boxes/wires.

11. Prevention and management of catheter complications

The main complications are:

(a) Catheter-related infection
(b) Catheter malfunction
(c) Catheter-related thrombosis

(a) Catheter-related infection.
Infection rates vary from 0.08 per 1000 days in oncology out-patients to 19 per 1000 catheter days in the critically ill (Fletcher & Bodenham 1999). Haemato-oncology infection rates probably lie somewhere within this range but catheter-related blood stream infections can be severe and life-threatening depending on the micro-organism involved. The Department of Health (Pratt et al 2001) has made recommendations for good practice regarding prevention, diagnosis and treatment of infections (and other aspects of central venous catheterization), which have recently been updated by Pellowe et al (2004).

There are three categories:

(i) A *catheter-related blood stream infection* is defined as at least two blood cultures positive with the same organism, obtained from at least two separate sites at different times, in association with evidence of colonization of the catheter with the same organism. The latter part of the definition can only be strictly fulfilled by removing the catheter.

(ii) An *exit site infection* presents with erythema, tenderness and occasionally a discharge at the insertion site.

(iii) A *tunnel infection* is characterized by pain and induration along the track of the catheter.

The incidence of these infections varies in different centres with different groups of patients and different practices.

The management of catheter infections remains controversial. Attempts should be made to make a microbiological diagnosis by culturing blood from all catheter lumina, a peripheral sample of blood and the exit site before commencing antibiotics. However, in clinical practice, it is usual for broad-spectrum antibiotics to be initiated while awaiting culture results. Table 3 summarizes current recommendations based upon consensus and the literature, although the decision to salvage or remove a catheter should be made following discussion with the microbiologist and after consideration of the patient’s clinical status and his position on the treatment pathway. Recent evidence suggests that *in situ* use of glycopeptides may be effective for coagulase negative staphylococcal infections (Giacometti et al 2005; Ley et al 1996). The ‘antibiotic lock’ technique may also be effective in reducing catheter-related bacteraemia (Garland et al 2005; Kim et al 2006; Fernandez-Hidalgo et al 2006; Carratala 2002; Rijnders et al 2005). Certain organisms carry a much greater risk of treatment failure and disseminated infection (See Table 3). A catheter lock solution containing citrate and taurolidine (TauroLock™) has been used particularly in the setting of haemodialysis catheters (Allon 2003; Betjes & van Agteren 2004), and is designed to render the internal flow passages resistant to clot formation and hostile to bacterial and fungal growth. This may also prove useful in the haemato-oncology setting, but requires further evaluation.

It is recommended that administration sets are changed every 72 hours when used for continuous infusions of solutions, but these should be changed more frequently if used for intermittent therapies, blood or lipids (NICE 2003; RCN 2005). Needle-free connectors must be changed in accordance with manufacturer’s recommendations (MHRA 2005).

(b) Catheter malfunction
Partial and complete catheter blockage is evidenced by difficulty in aspirating blood or infusing fluid. Forcible introduction of fluid down an obstructed lumen may cause catheter rupture. Catheter occlusion may include blockage due to kinking of the catheter, “pinch off syndrome”, occlusion of the catheter tip on the vessel wall, fibrin sheath or fibrin flap or luminal thrombus, or migration of the tip into a smaller vessel. Plain X-ray or a catheter contrast study may be helpful in confirming the diagnosis. Initially, fibrin sheaths manifest with catheter dysfunction, progressing to complete failure. They are usually discovered 1-2 weeks after placement (Crain et al 1998). Infusion substances can penetrate between the catheter wall and the fibrin sheath in a retrograde manner, along the catheter to the site of venous insertion, and even out to perivascular and subcutaneous layers. This can lead to cutaneous or subcutaneous necrosis. Untreated fibrin sheaths are associated with increased risk of complications, but interventional radiologists may be able to temporarily salvage catheter function by using percutaneous, intravascular fibrin sheath stripping via a trans-femoral approach (Knutstad et al 2003).

Where catheter occlusion is due to thrombus without symptomatic thrombosis, instillation of Hepsal (heparin sodium 10 units/ml) may be effective. If not, urokinase 10,000 u/ml reconstituted in 4ml normal saline may be tried, using 2ml of solution into each catheter lumen and ensuring that intra-luminal volumes only are instilled. Urokinase is manufactured by Medac and is available on a named patient basis. The solution should be injected gently into the catheter with a push-pull action to maximize mixing within the lumen. The lumen should then be clamped and left for at least 2-3 hours. The catheter should then be unclamped and the solution containing disaggregated clot aspirated (Dougherty 2004; Gabriel 1999). It has not been shown to be cost-effective or clinically necessary to leave the solution in the lumen for longer periods, such as between episodes of haemodialysis.

Very recently, an alternative urokinase preparation called Syner-KINASE has become available. This is manufactured by Syner-med and has been licensed in the UK for clearing blocked intravenous catheters. It is highly purified, extracted from human urine, and tested by PCR to exclude viral contamination. This is said to be free of the technical problems associated with manufacture which were associated with the previous brands of urokinase.

An alternative to urokinase is Cathflo Activase (Alteplase) which is a recombinant human tissue plasminogen activator (t-PA) (Deicher SR et al, 2002). Again, this is available on a named patient basis and is manufactured by Genentech.

Other reasons for catheter malfunction can include damage to the catheter. For example, “pinch off” as described earlier, or kinking of the catheter. Occasionally the tip of the catheter can migrate, particularly if the catheter is short and the tip initially lies in the upper superior vena cava or brachiocephalic vein. This may result in the catheter ceasing to function. Repeat chest X-rays may help in diagnosing these problems.

Internal repair of a damaged catheter is no longer recommended due to risk of infection and/or air embolus. External repairs of damaged catheters can be performed using kits provided by the manufacturers.

(c) Catheter-related thrombosis
Catheter-associated thrombosis may be spontaneous, or may result from a prothrombotic state associated either with underlying malignancy or treatment, particularly with L-asparaginase, thalidomide or lenalidamide. The catheter will normally require removal if thrombosis is confirmed. Intraluminal thrombosis may be prevented by adhering to appropriate flushing protocols and ensuring good placement of the catheter tip (Table 2). The use of low dose warfarin is now contraindicated as it has been shown to be of no apparent benefit for the prophylaxis of symptomatic catheter-related thrombosis in patients with cancer (Couban et al 2005; Young et al 2005). Dose-adjusted warfarin may be superior but at the cost of an increased risk of bleeding. There are no published data concerning ideal levels of anticoagulation in thrombocytopenic patients or on the recommended duration of anticoagulant therapy in catheter-related thrombosis. If the catheter is removed due to confirmed thrombosis, therapeutic doses of low molecular weight heparin and warfarin should be given in non-thrombocytopenic patients. In thrombocytopenic patients low molecular weight heparin may be used, adjusting the dose in accordance with the level of thrombocytopenia. Full doses can be given if the platelet count exceeds 80x10^9/l (BCSH Guidelines, 2006), in the absence of bleeding and where renal function is normal. With platelet counts below this, the decision regarding heparin dose should be based on clinical need, the presence or absence of bleeding, and whether or not the platelet count increments with platelet transfusion. Renal function should be regularly monitored during treatment.

Anticoagulation should be continued for a period of approximately 3 months in uncomplicated cases, with a target INR of 2.5 (range 2.0-3.0) when warfarin is being used. If there is clinical or radiological evidence of persistent thrombus, anticoagulation should be continued for a longer period. Mechanical clot lysis or local application of thrombolytic drugs to rapidly restore vein patency can be effective if the vein is occluded with fresh thrombus. Collaboration with vascular surgical or interventional radiology teams is advised.

If the patient has a PICC, any swelling of the arm should be monitored. Swelling alone does not confirm thrombosis, and if suspected it must be confirmed radiologically, by Doppler ultrasound CT scanning or other imaging. If confirmed, the PICC should be removed and anticoagulants commenced as described previously.

12. Technique of catheter removal

Indications for catheter removal include (a) catheter-related infection, (b) persistent catheter occlusion, (c) catheter-related thrombus, (d) damaged catheter, and (e) the end of treatment.

Removal of a skin-tunnelled catheter requires local anaesthetic and minor surgical cut-down to remove the cuff if the catheter has been in situ for more than approximately three weeks. The patient should lie down to avoid air embolus. Simple traction can remove the catheter and cuff in catheters, which have been in less than three weeks. Gentle traction can be attempted, but if difficulty is encountered it is important to stop prior to the catheter breaking. Removal should be undertaken by experienced personnel. The platelet count should be greater than 50 x 10^9/l and the INR less than 1.5. Ideally, 12 hours should have elapsed after prophylactic low molecular weight heparin, and 18 hours after a therapeutic dose. The skin-tunnelled catheter can be removed under local anaesthetic. Use of a local anaesthetic agent containing epinephrine (w/v/1:200,000) may be helpful in the presence of thrombocytopenia and deranged clotting, to minimise
local bleeding. A small incision (2cm should be adequate) is made alongside the cuff and blunt dissection used to free the cuff and avoid catheter damage prior to removal. If the cuff is at the exit site it can be removed by enlarging the exit site wound. The intravascular portion should be removed safely prior to cutting the catheter (Galloway and Bodenham 2004). If the catheter tip is sheared off during removal, it is likely to embolise into the right heart pulmonary artery and will require urgent retrieval by vascular radiologists using a snare, under fluoroscopic guidance (Bessoud et al 2003). Internal repair of a damaged catheter is no longer recommended due to risk of infection and/or air embolus. External repairs of damaged catheters can be performed using kits provided by the manufacturers.

It is important to remove the catheter in the direction of the tunnel. The catheter should be inspected carefully after removal to ensure that it is complete, and, if infection is suspected, the tip should be sent to the microbiology department for culture. The cut-down site should be sutured with a fine 3/0 or 4/0 monofilament suture. Large incisions and thick sutures should be avoided as these scar badly. After removal, pressure should be applied to the exit point, tunnel and venotomy site and an occlusive dressing placed over the exit site to avoid air embolism.

Ports require surgical removal in theatre or equivalent. PICCs and short term, non-tunnelled catheters can be removed at the patients bedside and pressure applied. The tips should be sent for microscopy and culture if clinically indicated.

13. Recommendations for audit

A locally based audit should include patient identification data, diagnosis, date of catheter insertion, number of previous catheters, operator and department where the catheter was inserted, complications associated with the catheter, date of and reason for removal. Each unit should monitor their infection rates per 1000 catheter days to observe any changes or trends in infection rates and be mindful of the emergence of resistant bacteria.
Table 3: Recommendations for the management of catheter related infections

<table>
<thead>
<tr>
<th>Category of infection</th>
<th>Non-neutropenic patient</th>
<th>Neutropenic patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exit site infection</td>
<td>Remove catheter if no longer needed</td>
<td>Remove catheter if no longer needed</td>
</tr>
<tr>
<td></td>
<td>Treat empirically with *flucloxacillin</td>
<td>Initial empirical therapy including glycopeptide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treat for 10-14 days or longer until infection resolved</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Modify according to isolates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Remove catheter if evidence of progression or if blood cultures are positive for Staph. aureus, Pseudomonas spp, Mycobacterium spp., or fungi</td>
</tr>
<tr>
<td>Tunnel infection</td>
<td>Remove catheter if no longer needed</td>
<td>Remove catheter if no longer needed</td>
</tr>
<tr>
<td></td>
<td>Treat empirically with *flucloxacillin</td>
<td>Initial empirical therapy including glycopeptide</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treat for 10-14 days or longer until resolution of soft tissue infection. Modify according to isolates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If tracking continues to spread remove catheter</td>
</tr>
<tr>
<td>Presumed catheter-related bloodstream infection</td>
<td>Remove catheter if no longer needed</td>
<td>Remove catheter if no longer needed</td>
</tr>
<tr>
<td></td>
<td>Treat empirically with antibiotics targeted against isolates</td>
<td>Initial empirical antibiotic therapy. Modify according to isolates</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treat for at least 10-14 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Remove catheter if cultures remain positive after 48 hours of therapy or if proven catheter-related infection with Staph. aureus, Pseudomonas spp., Mycobacterium spp., or fungi</td>
</tr>
</tbody>
</table>

*Unless known to be colonized with MRSA, when a glycopeptide should be used*
Acknowledgements:

We are very grateful to Michaele Pocock for reading the manuscript and for providing helpful suggestions and further references.

References


